Clinical Trials on Bladder Absence

Total 3177 results

Hamlet Pharma AB

Recruiting

A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer

Czechia
Patrice Jichlinski

Recruiting

Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Non Muscle Invasive Bladder Cancer

Switzerland
Astellas Pharma Singapore Pte. Ltd.

Completed

A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden

Overactive Bladder (OAB)

Korea, Republic of, Australia
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Active, not recruiting

Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients (ACCRUE)

Non-muscle Invasive Bladder Cancer

China
Jeil Pharmaceutical Co., Ltd.

Completed

The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers

Overactive Bladder(OAB)

Korea, Republic of
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Completed

Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy

Non-muscle Invasive Bladder Cancer
En Chu Kong Hospital

Completed

Herbal Patch for Overactive Bladder

Overactive Bladder Syndrome

Taiwan
University of California, San Diego

Completed

Trial of Maintenance Therapy With Posterior Tibial Nerve Stimulation for Overactive Bladder

Overactive Bladder Syndrome

United States
Peking University

Withdrawn

PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer

Invasive Bladder Cancer Stage IV

China
Tongji Hospital

Unknown

"En Bloc" Resection of NMIBC: a Prospective， Single Centre，Randomized Study

Non-muscle Invasive Bladder Cancer
Beijing Pins Medical Co., Ltd
Beijing Hospital

Unknown

Clinical Trial of Sacral Neuromodulation for Treatment of Refractory Overactive Bladder (OAB)

Refractory Overactive Bladder

China
Astellas Pharma Inc

Terminated

A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)

Bladder Function

United States
University of Zurich

Completed

Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females

Overactive Bladder Syndrome

Switzerland
Novartis

Completed

A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder

Overactive Bladder Syndrome

United States
Novartis
Procter and Gamble

Completed

Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

Overactive Bladder (OAB)

United States
Ruijin Hospital

Not yet recruiting

Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

China
Mansoura University

Recruiting

Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer Patients

Non-Muscle Invasive Bladder Cancer

Egypt
Augusta University

Not yet recruiting

Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial

Overactive Bladder | Overactive Bladder Syndrome
Association Francaise d'Urologie

Not yet recruiting

AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer (TVNIM-AFU)

Non-Muscle-Invasive Bladder Cancer
Uro-1 Medical

Recruiting

Use of Repris Needle in Bladder Injection

Overactive Bladder Syndrome

United States
Fisiocore LC,SL

Recruiting

Efficacy of Transcutaneous Versus Percutaneous Posterior Tibial Nerve Stimulation in the Overactive Bladder.

Overactive Bladder Syndrome

Spain
National Taiwan University Hospital

Completed

Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes

Overactive Bladder Syndrome

Taiwan
National and Kapodistrian University of Athens

Completed

Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB)

Overactive Bladder (OAB)

Greece
CG Oncology, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (CORE-001)

Non Muscle Invasive Bladder Cancer

United States, Korea, Republic of
Taipei Medical University Shuang Ho Hospital

Completed

Effect of Ureteral Stents Length and Location on Related Symptom

Lower Urinary Tract Symptoms | Overactive Bladder Syndrome

Taiwan
Astellas Pharma Singapore Pte. Ltd.

Completed

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

Overactive Bladder (OAB)

Korea, Republic of, Taiwan
Ataturk Training and Research Hospital

Unknown

Effects of Kinesio Taping Application in Women With Overactive Bladder

Overactive Bladder Syndrome

Turkey
Astellas Pharma Inc

Completed

Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

Overactive Bladder (OAB)

Japan
Catalan Institute of Health

Completed

Effectiveness of a Structured Intervention to Optimize the Use of Mirabegron

Overactive Bladder Syndrome
Buddhist Tzu Chi General Hospital

Unknown

Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP

Overactive Bladder Syndrome

Taiwan
Poitiers University Hospital

Unknown

Evaluation of Immediate Preoperative Instillation (IPOI) of Mitomycin C Compared to Early Postoperative Instillation (IPOP) in Non-muscle Invasive Bladder Cancer (IPOI vs IPOP)

Non Muscle-invasive Bladder Cancer

France
University of Oklahoma

Completed

Vaginal Electrical Stimulation Versus Neuromodulation (Estim)

Refractory Overactive Bladder

United States
Astellas Pharma Inc
GlaxoSmithKline

Withdrawn

A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication

Overactive Bladder (OAB)
UroGen Pharma Ltd.

Withdrawn

A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) (NMIBC TURBT HG)

Non Muscle Invasive Bladder Cancer

Israel
National Taiwan University Hospital

Unknown

Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients

Overactive Bladder Syndrome

Taiwan
The University of Texas Health Science Center at...

Completed

Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy

Invasive Bladder Cancer Stage II

United States
Sheffield Teaching Hospitals NHS Foundation Trust

Completed

Peripheral Electrical Stimulation for the Treatment of Overactive Bladder (PESTOB)

Idiopathic Overactive Bladder

United Kingdom
National Taiwan University Hospital

Unknown

Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug

Overactive Bladder Syndrome

Taiwan
Pfizer

Completed

Fesoterodine "add-on" Male Overactive Bladder Study

Overactive Bladder Syndrome

United States, Canada, Greece, Brazil, Korea, Republic of, Singapore, Poland, India, Norway, Slovakia, Spain, Belgium, Philippines, Netherlands, Sweden, Thailand, Malaysia, Germany, Colombia
Avera Pharmaceuticals

Terminated

Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity

Overactive Bladder Syndrome

Netherlands, United Kingdom
Novartis

Completed

A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.

Overactive Bladder Syndrome

United States
Jonsson Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Stage IV Bladder Cancer AJCC v8 | Stage IVA Bladder Cancer AJCC v8 | Stage IVB Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma

United States
Emory University

Terminated

Adjuvant Radiation for High Risk Bladder Cancer

Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca

Completed

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Adenocarcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder | Metastatic Bladder Cancer | Non-Transitional Cell Carcinoma of the Urothelial Tract | Small Cell of the Bladder

United States
University of Southern California
National Cancer Institute (NCI); GlaxoSmithKline

Terminated

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

Recurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder

United States
University of California, Davis
National Cancer Institute (NCI); IO Biotech

Recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
Chinese PLA General Hospital
Beijing GeneX Health Technology Co., Ltd

Recruiting

Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity Detection

Muscle-Invasive Bladder Carcinoma

China
Teesside University
South Tees Hospitals NHS Foundation Trust

Not yet recruiting

Developing a Simple Test to Diagnose Overactive Bladder

Overactive Bladder | Overactive Bladder Syndrome | Detrusor Overactivity
Turku University Hospital
Nordic Urothelial Cancer Group

Recruiting

Nordic Cystectomy Study II - Albumin (NorCys-Alb)

Bladder Cancer | Invasive Bladder Cancer

Finland
CAMC Health System

Completed

Intravenous Lidocaine for Cystectomy Procedures (Lidocaine)

Invasive Bladder Cancer

United States

Clinical Trials on Bladder Absence

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations